全文获取类型
收费全文 | 81402篇 |
免费 | 5895篇 |
国内免费 | 2564篇 |
专业分类
耳鼻咽喉 | 832篇 |
儿科学 | 1920篇 |
妇产科学 | 1138篇 |
基础医学 | 10406篇 |
口腔科学 | 1552篇 |
临床医学 | 7198篇 |
内科学 | 12276篇 |
皮肤病学 | 2540篇 |
神经病学 | 6066篇 |
特种医学 | 1741篇 |
外国民族医学 | 6篇 |
外科学 | 5001篇 |
综合类 | 11214篇 |
现状与发展 | 7篇 |
预防医学 | 6376篇 |
眼科学 | 983篇 |
药学 | 12453篇 |
32篇 | |
中国医学 | 4082篇 |
肿瘤学 | 4038篇 |
出版年
2024年 | 111篇 |
2023年 | 1151篇 |
2022年 | 2307篇 |
2021年 | 3267篇 |
2020年 | 2615篇 |
2019年 | 2661篇 |
2018年 | 2690篇 |
2017年 | 2615篇 |
2016年 | 2515篇 |
2015年 | 2648篇 |
2014年 | 4655篇 |
2013年 | 5322篇 |
2012年 | 4501篇 |
2011年 | 5096篇 |
2010年 | 4106篇 |
2009年 | 3984篇 |
2008年 | 4013篇 |
2007年 | 3871篇 |
2006年 | 3408篇 |
2005年 | 3188篇 |
2004年 | 2794篇 |
2003年 | 2447篇 |
2002年 | 2048篇 |
2001年 | 1726篇 |
2000年 | 1576篇 |
1999年 | 1435篇 |
1998年 | 1143篇 |
1997年 | 1157篇 |
1996年 | 1028篇 |
1995年 | 996篇 |
1994年 | 869篇 |
1993年 | 659篇 |
1992年 | 652篇 |
1991年 | 618篇 |
1990年 | 488篇 |
1989年 | 471篇 |
1988年 | 467篇 |
1987年 | 406篇 |
1986年 | 368篇 |
1985年 | 539篇 |
1984年 | 498篇 |
1983年 | 400篇 |
1982年 | 444篇 |
1981年 | 351篇 |
1980年 | 315篇 |
1979年 | 269篇 |
1978年 | 213篇 |
1977年 | 157篇 |
1976年 | 150篇 |
1975年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
42.
43.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
44.
目的:观察稀土化合物硝酸钇[Y(NO3)3]亚慢性(90 d)暴露对大鼠学习记忆能力的影响,并探究其可能的机制,为全面评估稀土元素钇的健康风险提供科学依据。方法:选用刚离乳(PND21)SD雌性大鼠,根据质量随机分为4组,分别为对照组(ddH2O),Y(NO3)3低剂量组[10 mg/(kg·d)]、中剂量组[40 mg/(kg·d)]和高剂量组[160 mg/(kg·d)],每组15只。连续灌胃受试物90 d后进行旷场实验、高架十字迷宫实验、转棒实验、Morris水迷宫实验。水迷宫检测后,每组取5只雌鼠心脏原位灌注,进行脑组织病理学检查。每组剩余10只雌鼠摘取脑组织,紫外分光光度计检测雌鼠大脑皮质和海马中谷氨酸(Glu)的含量;Western blot检测海马组织中N-甲基-D-天冬氨酸(NMDA)受体蛋白表达情况。结果:与对照组相比,硝酸钇90 d暴露后,转棒实验中160 mg/(kg·d)剂量组大鼠在棒时间、在棒圈数、掉落速度明显升高(P<0.05)。在Morris水迷宫定位航向实验第4天时,40、160 mg/(kg·d)剂量组大鼠逃避潜伏期明显降低(P<0.05);Morris水迷宫空间探索实验中,40 mg/(kg·d)剂量组大鼠穿越平台次数、目标象限游泳时间明显增加(P<0.05);160 mg/(kg·d)剂量组穿越平台次数、进入目标象限次数、目标象限游泳时间明显增加(P<0.05);160 mg/(kg·d)剂量组大鼠东北、东南、西南象限的逃避潜伏期明显低于西北象限的逃避潜伏期(P<0.05)。160 mg/(kg·d)剂量组大鼠海马中Glu含量和NMDA受体NR1含量均明显低于对照组(P<0.05)。40和160 mg/(kg·d)剂量组大鼠海马中NMDA受体NR2A含量明显低于对照组(P<0.05)。结论:硝酸钇亚慢性(90 d)暴露可以引起雌性大鼠空间学习记忆能力增强;硝酸钇可能通过降低海马组织神经元细胞外Glu含量,抑制NMDA受体激活,增强雌性大鼠的空间学习记忆能力。 相似文献
45.
46.
47.
48.
《Journal of Science and Medicine in Sport》2019,22(9):1038-1043
ObjectivesGrowing evidence of the importance of motor competence for developing a healthy lifestyle has been established in the last decade. Nonetheless, no single instrument or observation tool have been able to fully measure this construct, particularly because most were built for the diagnosis of children in risk for motor impairment; are limited to a few years of the developmental span; lack objectivity in the assessment protocols; or do not include the locomotor, stability, and manipulative components. This led to the difficulty of comparing researches, and longitudinally follow children into adulthood. Recently, a novel proposal to assess motor competence was presented - the Motor Competence Assessment (MCA) - and this study aims to present the MCA normative data from 3-to-23 years.Design and methodsTwo thousand and eighty-seven participants (1102 boys) between 3 and 23 years of age were evaluated in the MCA (standing long jump, 10 m shuttle run, throwing velocity, kicking velocity, lateral jumps, shifting platforms). Results for each test were introduced in the LMS Chartmaker 2.3. The best model for test and sex was used, resulting in normative curves and percentile values.ResultsFinal norms showed a good fit to the instrument developmental expectations, allowing to differentiate and classify performances along the age interval.ConclusionsThe MCA age- and sex- normative values allow to assess motor competence from childhood to early adulthood. Future directions will include obtaining a total MCA score and the normative scores for the MCA components (stability, locomotion, object control), and to expand the norms to adulthood and old age. 相似文献
49.
50.
Is it possible to make a diagnosis of raw,heated, and baked egg allergy in children using cutoffs? A systematic review
下载免费PDF全文
![点击此处可从《Pediatric allergy and immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)